Top Markets
Coin of the day
Ocean Biomedical, Inc. Ocean Biomedical, Inc.

Ocean Biomedical, Inc.

OCEAW
株式のランク #33294
Ocean Biomedical, Inc. is a biopharmaceutical enterprise primarily engaged in... Ocean Biomedical, Inc. is a biopharmaceutical enterprise primarily engaged in identifying and advancing novel therapeutic agents. Their research and development efforts span several key disease areas, including cancer, fibrotic conditions, infectious illnesses, and inflammatory disorders. The company's current development pipeline features both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are engineered to target Chi3l1 and are being investigated for treating non-small cell lung cancer and glioblastoma multiforme, a type of brain tumor. Furthermore, Ocean Biomedical is progressing a small molecule therapeutic designed to interact with Chit1, intended for individuals afflicted with Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Their proprietary WPDS platform has generated three additional product candidates: a vaccine aimed at preventing malaria; a humanized monoclonal antibody treatment; and a small molecule treatment, with both malaria therapeutics specifically targeting the Plasmodium falciparum glutamic-acid-rich protein (PfGARP). The company is also developing a therapy for hospitalized patients suffering from COVID-19. Founded in 2019, Ocean Biomedical's operations are headquartered in Providence, Rhode Island.
株価
$0.0298
最終同期: 2026-02-10
時価総額
$7.94M
変化(1日)
0.00%
変化(1年)
664.10%
US
取引 Ocean Biomedical, Inc. (OCEAW)

カテゴリー

Ocean Biomedical, Inc.(OCEAW)の利益
2026 時点の利益 TTM: 0
Ocean Biomedical, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Ocean Biomedical, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益